The prospects for cancer gene therapy

International Journal of Immunopharmacology

Volumn 22, Issue 12, 2000, Pages 1025-1032

  De Giovanni, Carla ^a   Nanni, Patrizia ^a   Forni, Guido ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHEMOKINE; CYTOKINE;

ANTIGEN PRESENTING CELL; ARTICLE; CANCER; CANCER CELL; CANCER GROWTH; GENE TARGETING; GENE THERAPY; GENETIC CODE; HUMAN; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; METASTASIS; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VACCINATION;

EID: 0034532351     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(00)00066-7     Document Type: Short Survey

References (25)

1. Strategies for enhancing tumor immunogenicity (or how transform a tumor cell in a Frankenstenian APC)
2. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years
3. Human gene therapy
4. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: A proposed mechanism for bystander effect
5. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
6. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
7. Antisense approaches to the gene therapy of cancer - 'Recnac'
8. Intrabodies: Turning the humoral immune system outside in for intracellular immunization
9. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
10. ONYX-015: Clinical data are encouraging
11. 5-Fluorocytosine induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory
12. Molecular approaches to cancer immunotherapy
13. The immune response elicited by mammary adenocarcinoma cells transduced with γ-interferon and cytosine deaminase genes cures lung metastases by parental cells
14. Antiangiogenic gene therapy
15. Gene therapy strategies for tumor antiangiogenesis
16. Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice
17. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
18. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells
19. Cytokines, tumour-cell death and immunogenicity: A question of choice
20. Antitumor efficacy of adenocarcinoma cells engineered to produce IL-12 or other cytokines compared with exogenous IL-12
21. The advent of the 'unpatient'
22. Specific and nonspecific immunity in the prevention of spontaneous tumours
23. Tumors: A hundred and one ways to fool the immune system
24. Detection and clinical importance of micrometastatic disease